Assessment of Diagnostic Yield Using a Robotic Navigational Bronchoscopy System With CBCT

Lung Cancer Clinical Trial

Official title:

A Prospective Investigation to Assess the Diagnostic Yield of Using a Robotic Navigational Bronchoscopy System With Adjunct Real-time Imaging

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06084208
• Other study ID #: ISI-ION-EU2-2023
• Status: Recruiting
• Phase: N/A
• Start date: September 15, 2023
• Est. completion date: May 31, 2026

Study information

• Verified date: October 2023
• Source: Intuitive Surgical
• Contact: Carine Van den Abeele
• Phone: +41 79 656 95 48
• Email: Carine.vandenabeele[@]intusurg.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this research study is to evaluate the effectiveness of the ION endoluminal system at reaching and obtaining biopsies from lung nodules when used in combination with 3-dimensional imaging such as CT scans. The learning curve of the procedure will be assessed and data on safety will also be collected.

Description:

This is a prospective, interventional, single-centre, dual-arm study which will be conducted in the Netherlands and will involve up to 131 patients undergoing a pulmonary nodule biopsy using the Ion Endoluminal System in conjunction with 3D imaging. Outcomes in these patients will be compared to 91 propensity score matched Cone Beam CT- Navigational Bronchoscopy (CBCT-NB) controls obtained from the site's existing CBCT-NB database.

The objectives of the study are focused on evaluating the procedure learning curve and characteristics of the pulmonary nodule biopsy procedure, including diagnostic yield, rate of tool in nodule, sensitivity for malignancy and safety.

A learning curve analysis will be retrospectively performed to determine when both operators have reached competency with the Ion Endoluminal System. Criteria for passing the learning curve for measuring proficiency in the CUSUM will be diagnostic yield. Additional parameters like tool in lesion and procedure durations will also be monitored.

All subjects will be followed up at 1 week and 1 month after the procedure. If the biopsy did not provide a diagnosis or did not show cancer, then they will have further follow up at 6 and 13 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 131
• Est. completion date: May 31, 2026
• Est. primary completion date: March 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient is aged 18 years or older at time of consent.

2. Patient is suitable for elective nodule biopsy via bronchoscopy under general anesthesia per Investigator's discretion.

3. Patient has solid or semi-solid pulmonary nodule(s) of =6 mm and =3 cm in largest dimension (based on pre-procedure CT scan).

4. Pulmonary nodule(s) intended for biopsy during the study procedure is (are) located at least 4 (=4) airway generations out (trachea = generation 0, e.g. subsegmental bronchi or beyond) based on pre-procedure CT scan.

5. Patient has a moderate to high risk of lung cancer based on clinical, demographic, and radiologic information or with suspected metastatic disease. High risk for malignancy patients are eligible if a biopsy is required or requested prior to intervention.

6. Patient is willing and able to give written informed consent for Clinical Investigation participation.

7. Patient is not legally incapacitated or in a legal/court ordered institution.

Exclusion Criteria:

1. Patient has a lack of fitness or exercise capacity to undergo bronchoscopy under general anesthesia as determined by Investigator prior to procedure.

2. Patient with type 1 pure ground glass opacity target nodule(s) intended for biopsy during study procedure.

3. Presence of bullae(s) with a size of >1 cm on pre-procedure CT scan located in close proximity to target nodule(s) and near the planned trajectory of the biopsy instruments.

4. Presence of mediastinal nodal disease on pre-procedure CT or PET-CT scan.

5. Patient with American Society of Anesthesiologists Classification (ASA) =4.

6. Patient underwent a pneumonectomy.

7. Any invasive concomitant procedure (outside of lymph node staging) not related to the pulmonary nodule(s) or suspected disease state.

8. Female patient of child-bearing potential who is unable to take adequate contraceptive precautions or is known to be pregnant, and/or breast feeding.

9. Patient has a documented medical history of uncorrectable coagulopathy, bleeding, or platelet disorder.

10. Patient is taking antiplatelet or anticoagulant medications that cannot be stopped per standard practice.

11. Patient is currently participating or has participated in another Clinical Investigation within the past 30 days, such as interventional trials or trials with experimental agents or agents of unknown risk, that may affect the endpoints of this Clinical Investigation.

12. Investigator, in their professional opinion, has decided that it is in the patient's best interest to not participate in the Clinical Investigation.

13. Patient is not willing to comply with post study procedure participation requirements.

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Device:
• Biopsy with the Robotic- Ion Endoluminal System with Adjunct Real-time Imaging
Biopsy with the Robotic- Navigational Bronchoscopy System with Cone Beam Computed Tomography (CBCT)

Locations

Country	Name	City	State
Netherlands	Radboud University Medical Center	Nijmegen

Sponsors (1)

Lead Sponsor	Collaborator
Intuitive Surgical

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Rate of procedure-related Adverse Events through 30 days post-procedure	The study's safety endpoint is the rate of procedure-related Adverse Events through 30 days post-procedure	30 days
Other	Procedure-related characteristics	Procedure time (from catheter inserted into the patient's airways to catheter removed from the patient's airways) will be reported	At time of the biopsy procedure (Day 0)
Other	rEBUS visualization characteristics	The frequency of use of a concentric rEBUS visualization view during the biopsy will be summarized.	At time of the biopsy procedure (Day 0)
Other	Biopsy workflow	The sequence of biopsy tools used will be summarized.	At time of the biopsy procedure (Day 0)
Primary	Diagnostic yield of sample(s) obtained (post learning curve)	Diagnostic yield is the number of nodules in which the procedure was diagnostic (either malignant or non-malignant), relative to the total number of attempted navigation procedures	Up to 13 months post procedure]
Secondary	Sensitivity for malignancy of sample(s) obtained	Sensitivity for malignancy of samples is assessed as the number of subjects with a malignant condition determined through the study procedure (true positives) relative to the number of subjects with an underlying malignant disease state (true positives + false negatives).; The subjects underlying disease state will be determined by follow-up diagnostic interventions or treatment decisions/interventions, and/or radiographic follow-up.	Up to 13 months post procedure
Secondary	Rate of achieving biopsy tool position within the targeted nodule(s) as confirmed by CBCT 3D imaging	The rate of Tool in Nodule is how often the biopsy tool to sample the tissue is positioned directly within the nodule before the sample is taken.; If biopsy forceps are used, it is how often the instrument is surrounding the nodule before the sample is taken.	At time of the biopsy procedure (Day 0)